A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis

Inclusion Criteria: Treatment naive patients of allergic bronchopulmonary aspergillosis (ABPA) defined by the presence of all the following: * asthma * immediate cutaneous hyperreactivity on Aspergillus skin test or A.fumigatus specific IgE levels \>0.35 kUA/L * elevated total IgE levels \>1000 IU/mL and, two of the following features: * presence of precipitating antibodies against A.fumigatus in serum * fixed or transient radiographic pulmonary opacities * total eosinophil count \>1000/µL * bronchiectasis on HRCT chest Exclusion Criteria: * Intake of systemic glucocorticoids for more than three weeks in the preceding six months * Exposure to azoles in the last six months * Immunosuppressive states such as uncontrolled diabetes mellitus, chronic renal failure, chronic liver failure and others * Patient on immunosuppressive drugs * Pregnancy * Enrollment in another trial of ABPA * Failure to provide informed consent